Fortune Article

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.

Happy Monday, readers! I hope you enjoyed your weekend.

Fortune‘s 2019 Global Forum began on Monday in Paris. I encourage readers to catch up on the panels, one-on-one interviews, and conversations with some of the most consequential figures in business and government.

On the health care front, here’s what I found intriguing: A back-and-forth between GE Healthcare CEO Kieran Murphy and Dassault Systèmes chief executive Bernard Charlès on the future of digital health.

These two high-flying chief executives are trying to turn the stuff of science fiction into medical reality. For instance, Dassault’s Charlès says his company aims to create a “virtual twin of a human.” That includes simulating human hearts and brains before having to perform procedures (and to assist in drug development).

Murphy and GE Healthcare—which has invested heavily in A.I. and machine learning in order to streamline medical services—have developed technologies to detect a lung collapse from an X-ray and make it a top priority for physicians or technicians.

More on this panel here. Read on for the day’s news.

Sy Mukherjee
sayak.mukherjee@fortune.com
@the_sy_guy

DIGITAL HEALTH

Juul is getting sued... Again. Vaping giant Juul is facing yet another lawsuit, this time by California officials for allegedly marketing products to teens. California is trying to force Juul to pay the costs of addiction treatment and prevention for e-cig products; Juul (which seems to be taking a soft touch since the massive backlash against e-cigarettes and plethora of lawsuits against the company) says that it is dedicated to "resetting the vapor category." (Fortune)

INDICATIONS

Another biosimilar gets approved. But when will it hit the market? Pfizer has become the latest company to win FDA approval for a biosimilar approval to AbbVie's best-selling drug Humira. Humira is a treatment that brought in $20 billion in revenues last year alone. Part of the reason, as I explored in my feature a few months ago, is AbbVie's aggressive patent strategy against would-be biosimilar competitors (these are the analogues to generic versions of chemical drugs). Sure enough—Pfizer’s Abrilada, its Humira biosimilar, can't get onto the market until 2023 (despite an approval today) due to the patent dance. (FiercePharma)